The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin

Journal of Neural Transmission

Volumn 104, Issue 4-5, 1997, Pages 561-564

  Martin, P ^a   Waters, N ^a   Carlsson, A ^a   Carlsson, M L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Locomotion; M100907; MK 801; Ritanserin

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; NEUROLEPTIC AGENT; RITANSERIN; SEROTONIN 2A ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MECHANISM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FLUOROBENZENES; MALE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; PIPERIDINES; RITANSERIN; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 0030766908     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01277672     Document Type: Article

References (16)

1. Baxter G, Kennett G, Blaney F, Blackburn T (1995) 5-HT2 receptor subtypes: a family reunited? Trends Pharmacol Sci 16: 105-10
2. Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1990) 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13: 500-6
3. Bunney BG, Bunney WE, Carlsson A (1995) Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 1205-1215
4. Carlsson ML (1995) The selective 5-HT2a-receptor antagonist MDL100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse implications for psychosis. J Neural Transm [Gen Sect] 100: 225-237
5. 2 receptor antagonist, ritanserin. J Neurochem 59: 1459-1466
6. Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial [see comments]. Br J Psychiatry 163: 451-5
7. Hansson LO, Waters N, Winblad B, Gottfries CG, Carlsson A (1994) Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J Neural Transm [Gen Sect] 98: 217-35
8. Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968-81
9. Leysen JE (1990) Gaps and peculiarities in 5-HT2 receptor studies. Neuropsychopharmacol 3: 361-69
10. Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27: 600-11
11. Martin P, Waters N, Holm S, Carlsson A, Carlsson ML (1995) The stimulation of forward locomotion by MK-801 is abolished by low doses of the 5-HT2a antagonist MDL 100,907. 25th Annual Meeting, Society for Neuroscience, 21, part 3, p 2057
12. Middlemiss DN, Tricklebank MD (1992) Centrally active 5-HT receptor agonists and antagonists. Neurosci Biobehav Rev 16: 75-82
13. Shi WX, Nathaniel P, Bunney BS (1995) Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. J Pharmacol Exp Ther 274:735-40
14. Van Wijngaarden I, Tulp MT, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 188: 301-12
15. Waters N, Carlsson A, Hansson L (1994) An animal model of schizophrenia based on multivariate analysis monoaminergic biochemistry and behaviour 24th Annual Meeting, Society for Neuroscience, 20, part 1, p 825
16. Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83:7104-8